Pilot Study Yields Insights on Underserved Groups in Bleeding Disorders Community
While it is generally understood that the social determinants of health (SDOH) are significant factors contributing to an individual’s overall health, research specific to SDOH and its impact upon the bleeding disorders community has been rather…
Navigating Open Enrollment for Private Insurance This Fall
Speakers: Aaron Blocker, Matt Delaney, Miriam Goldstein, Johanna Gray Description: With open enrollment just around the corner -- and with many changes coming  out of Washington DC and state capitols --…
The Odyssey of FX: Voices, Symptoms, and the Evolution of Care
Speakers: Brian Branchford, MD; Ariel LoraineDescription: Explore the experience of factor X deficiency (FX), an ultra-rare bleeding disorder, from understanding mild to severe bleeding, joint complications, and…
Novo Submits New Application for Its Investigational SubQ Hemophilia Therapy
Novo Nordisk has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for Mim8 (denecimig), an investigational bispecific antibody therapy. The antibody promotes coagulation by binding two key proteins (…
Discover a Treatment Option from HEMA Biologics for the Hemophilia Community
Speakers: Guy Young, MDDescription: Join Dr. Young, speaking on behalf of HEMA Biologics, for an informative conversation about a treatment option for hemophilia A or B with inhibitors. This session will share…
Samantha Short
Evan Rahaeuser
Heather Conner
Amy Walker
Star Therapeutics Announces New Financing for Investigational VWD Treatment
Star Therapeutics recently announced new financing totaling $125 million that will help the San Francisco-based biotechnology company continue to develop their investigational von Willebrand disease therapy VGA039. The U.S. Food and Drug…